About the drug
Description
Marketing Authorization
Scheme-instruction
News
Publications and reports
Advantages
New Guidance
Expert opinion
Team
Pharmacovigilance
Contacts
About the drug
- Description
- Marketing Authorization
- Guidance
Advantages
Expert opinion
Team
Pharmacovigilance
News
Contacts
News
30.06.2019
CardioSystemPharma deepens international cooperation with the medical community of the USA and Europe
18.06.2019
The advantages of Normacor® have been demonstrated to the heads of Chinese cardiac surgery clinics in several leading cardiac surgery centers in Moscow
17.05.2019
ChemRar Group introduces innovative products to the Chinese market
05.08.2016
On June 20, 2016, the Ministry of Healthcare of the Russian Federation issued Marketing Authorization No. ЛП-003 689 for innovative cardioplegic drug - Normacor®
.png){kind=small}
.png){kind=small}
